EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury
February 15, 2023 07:00 ET
|
EuMentis Therapeutics, Inc.
EuMentis is developing novel therapeutics with clinically validated mechanisms for the treatment of neurodevelopmental and neuropsychiatric conditionsEuMentis plans to initiate Phase 2 clinical trials...
EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury
February 08, 2023 07:00 ET
|
EuMentis Therapeutics, Inc.
Under the DoD award, EuMentis will conduct preclinical TBI studies in validated large animal model in collaboration with Dr. Todd Killbaugh at the Children’s Hospital of Philadelphia (CHOP) and plans...